Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer.
about
Targeting the indoleamine 2,3-dioxygenase pathway in cancerIndoleamine 2,3 dioxygenase in intestinal diseaseImmune activation and degradation of tryptophan in coronary heart diseaseSelective paired ion contrast analysis: a novel algorithm for analyzing postprocessed LC-MS metabolomics data possessing high experimental noiseVitamin E status and quality of life in the elderly: influence of inflammatory processes.Potential role of tryptophan and chloride in the inhibition of human myeloperoxidase.BAR the door: cancer suppression by amphiphysin-like genesTryptophan degradation in women with breast cancer: a pilot studyAn observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function.Fatigue in patients with lung cancer is related with accelerated tryptophan breakdown.A novel serum metabolomics-based diagnostic approach for colorectal cancerFormation of an N-formylkynurenine-derived fluorophore and its use for measuring indoleamine 2,3-dioxygenase 1 activity.Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.Metabolic signatures of extreme longevity in northern Italian centenarians reveal a complex remodeling of lipids, amino acids, and gut microbiota metabolism.Kynurenine pathway metabolites in humans: disease and healthy States.Immuno-regulatory function of indoleamine 2,3 dioxygenase through modulation of innate immune responses.Utility of kynurenic acid for non-invasive detection of metastatic spread to lymph nodes in non-small cell lung cancerHelicobacter pylori and serum kynurenine-tryptophan ratio in patients with colorectal cancerPicolinic acid in patients with chronic hepatitis C infection: a preliminary reportPre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents.Translational approaches to treatment-induced symptoms in cancer patients.Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growthEffect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study.Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinomaIndoleamine 2,3-dioxygenase and tumor-induced toleranceCharacterization of the microbiome of nipple aspirate fluid of breast cancer survivors.Functional metagenomic profiling of intestinal microbiome in extreme ageing.Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases.Prognostication of diffuse large B-cell lymphoma in the rituximab era.Branched-chain amino acids as pharmacological nutrients in chronic liver disease.The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced toleranceHost indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway: Relevance to cancer-related fatigue.Prevention and treatment of cancers by immune modulating nutrients.Mechanisms of Inflammation-Associated Depression: Immune Influences on Tryptophan and Phenylalanine Metabolisms.Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c+ Myeloid Dendritic Cell Maturation Arrest, Induction of the Kynurenine Pathway, and Regulatory T Cell Activation.The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan MetabolismSerum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
P2860
Q26775471-F05D8D21-D4DE-4787-8DFF-E3086163FDF7Q27025063-148E618B-94DE-48CB-B529-FFB4F5D26AB8Q28180117-7AA63142-F943-4EE6-AD7F-698409688F9CQ30893057-F6C4DFC1-25F7-43FC-8FD3-970622D1CBECQ33600013-3F3AD8D3-CD09-4E0A-B45C-2664E12A159FQ33818264-0BD64391-A18E-4442-810C-DE21E4C72810Q33870256-65181934-7CE1-499C-A369-71A69C5D3AB9Q33912950-F3CFCBF7-E2CF-4182-B970-DFD7A73B4B58Q33952214-FCE555B7-5509-422C-8C5F-08D36BF46165Q34277561-202238F8-17C6-455F-9D75-69338C8EE481Q34336333-DC1F45E5-1D05-4F1C-888E-5D673DD880E3Q34546698-C382DCA9-3D6B-44BB-BB99-F51D17AB084BQ34603340-A76CE6A0-8AA3-4810-A273-CB293C8217EDQ34616168-76307FCE-FCCD-41A1-BA58-D7C59535A372Q34618252-B87BFE30-AE4D-437D-8386-9FA02CC6A7A9Q34633683-3CEDE395-192D-4A2D-91A9-796363B5F98CQ34936678-C868CA3A-6E3E-4A1E-A4FD-A5EDFFCD0269Q34942871-090660E8-6ACA-4183-AFB0-2AB3F80C8B53Q35221827-9CCCDE47-C3A5-44DD-AF8E-8B46201A4F77Q36012223-032C962A-A22A-49FE-BE1E-0715AE06E00EQ36052673-9D58EDE6-900B-4863-8996-FEEE3A9FF365Q36143029-922AB2A3-F015-4D9F-8CA4-DC06C8016E0FQ36476449-82856AF7-96EB-4987-A1D5-F8BFB884C450Q36535642-F7E7EA01-ACA8-4EAD-84FF-AD015C6C09C0Q36747510-5EDBF132-B8F9-401B-923B-6D30C16EAE49Q36809762-572E6AE1-8F5F-44AD-84DA-E54C69908AA5Q37024095-AB61BD1C-DA7A-426A-A462-F9A7B5E32B8CQ37445053-B4DF4290-69D8-4E45-A3DB-A4BA4CB02A88Q37522460-E2BEAAC2-56DB-4168-8D67-544583F9C043Q37833087-E5BDB05A-58E8-4B15-84AB-1AC259CCE7C6Q37874555-71A3CCE7-EF65-417F-A9AE-C2C8F3BE2B00Q37959968-DFA0D36C-8971-489F-9899-8538C8DCD559Q38047057-EC934B69-E33C-4649-B28B-D56812933047Q38356502-8647DB14-06FB-49E9-814A-E13B1813240CQ38366476-C3558AE7-22AA-480E-A6B3-663EA1276261Q38718929-BC4FA190-4889-448B-82ED-4E838A322558Q38859547-553165A0-C5D4-4F60-9071-FD45F34125D3Q38892525-31E8CE0F-C41D-485B-9AA0-62684EF9E556Q38974424-8195F4D4-AC9F-4E61-8FDF-8E9A7F93E181Q39659168-08778F02-7B18-4A26-8E5A-CD9DAEEFCCE2
P2860
Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Serum tryptophan decrease corr ...... of life in colorectal cancer.
@ast
Serum tryptophan decrease corr ...... of life in colorectal cancer.
@en
type
label
Serum tryptophan decrease corr ...... of life in colorectal cancer.
@ast
Serum tryptophan decrease corr ...... of life in colorectal cancer.
@en
prefLabel
Serum tryptophan decrease corr ...... of life in colorectal cancer.
@ast
Serum tryptophan decrease corr ...... of life in colorectal cancer.
@en
P2093
P2860
P356
P1476
Serum tryptophan decrease corr ...... of life in colorectal cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600336
P407
P577
2002-06-01T00:00:00Z